Phathom Pharmaceuticals Inc.

PHAT

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase2 readout (Vonoprazan): Oct 2026. Short interest: 13.2% of float.

BiotechnologyCEO: Steven L. BastaIPO: 2019Website ↗

Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.

Recent News & Research

PubMed

Beyond gastric acid: pharmacologic modulation of the tumor microenvironment by vonoprazan and its drug-interaction implications for chemotherapy and immunotherapy.

# Investment Summary: Vonoprazan's Broader Oncology Potential **Clinical/Commercial Implications:** This research suggests vonoprazan (Phathom's potassium-competitive acid blocker) may have tumor microenvironment-modulating properties beyond acid suppression, with potential synergistic effects when combined with chemotherapy and immunotherapy regimens. The identification of drug-interaction mechanisms is significant because it could expand vonoprazan's addressable market from GI indications into oncology supportive care or potentially as an adjunctive therapy, though such applications would require substantial additional clinical validation and regulatory pathways. **Investor Relevance:** For PHAT investors, this represents exploratory data on a mechanism that could justify R&D investment in oncology combinations, but the practical commercialization timeline and clinical evidence bar remain unclear. Any oncology expansion would be contingent on prospective clinical trial data and

Oct 9, 2026

PubMed

Seven-day and fourteen-day vonoprazan-based dual or triple regimens for first-line Helicobacter pylori eradication.

# Investment Summary: Phathom Vonoprazan H. pylori Study **Clinical Finding:** This trial demonstrates that vonoprazan-based dual and triple therapy regimens achieve effective H. pylori eradication in 7-14 day treatment windows, potentially expanding treatment flexibility and improving patient compliance compared to standard regimens. **Commercial Implication:** Shorter, efficacious treatment courses could strengthen vonoprazan's (Voquezna) competitive positioning in the H. pylori market by offering clinicians convenient first-line options, though the magnitude of market share impact depends on eradication rates versus existing standards and real-world adoption rates in key markets. **Investor Note:** This evidence supports Phathom's value proposition for vonoprazan but requires monitoring of: (1) comparative efficacy data versus current standard-of-care, (2) uptake trajectories in core markets post-approval

Sep 15, 2026

PubMed

Efficacy and safety of vonoprazan, amoxicillin, and berberine hydrochloride triple therapy as first-line Helicobacter pylori eradication therapy.

# Investment Summary: PHAT Vonoprazan Triple Therapy Study **Clinical Finding:** A triple therapy combination of vonoprazan (PHAT's lead asset), amoxicillin, and berberine hydrochloride demonstrated efficacy as first-line H. pylori eradication treatment in a Chinese patient population. **Investment Implications:** This data expands the clinical evidence base for vonoprazan beyond PHAT's approved duodenal ulcer indication and supports potential label expansion into H. pylori eradication—a high-volume indication with significant market opportunity, particularly in Asia. However, the inclusion of berberine (a non-proprietary botanical compound) as part of the optimal regimen may limit vonoprazan's differentiation and commercial exclusivity in this use case. **Key Consideration:** Investors should monitor whether PHAT pursues regulatory pathways for H. pylori indications

Sep 14, 2026

PubMed

Eradication of Helicobacter pylori With Vonoprazan-Amoxicillin Dual Therapy as an Alternative for Bismuth-Based Quadruple Therapy: A Systematic Review and Noninferiority Meta-Analysis.

# Investment Summary: Vonoprazan Dual Therapy Meta-Analysis This meta-analysis demonstrates that vonoprazan-amoxicillin dual therapy achieves non-inferior H. pylori eradication rates compared to standard bismuth-based quadruple therapy, potentially simplifying treatment regimens and improving patient compliance. For Phathom (vonoprazan's commercializer), this finding expands the clinical evidence base for vonoprazan beyond its primary reflux disease indication, supporting label expansion opportunities and increased utilization in H. pylori treatment globally, particularly in markets where simpler regimens drive adoption. **Investor relevance:** Positive comparative efficacy data strengthens vonoprazan's competitive positioning in the large H. pylori treatment market and may support reimbursement arguments for broadening indications beyond GERD, though regulatory approval pathways and market adoption timing remain key execution variables.

Sep 1, 2026

PubMed

Stability-indicating RP-HPLC-DAD method for aspirin and vonoprazan using analytical quality by design and comprehensive greenness assessment.

# Investment Summary - Not Material **Assessment:** This article is **not relevant** to PHAT investment analysis. The paper describes an analytical chemistry method (HPLC) for measuring aspirin and vonoprazan stability in laboratory settings. While vonoprazan is PHAT's lead asset, this is a foundational analytical technique paper with no clinical data, efficacy insights, regulatory updates, or commercial implications discussed. Such manufacturing/QA methodology articles are routine and do not move clinical or commercial value assessments for investors tracking the company. **Recommendation:** Focus on clinical trial results, regulatory submissions (FDA letters), safety signals, competitive landscape shifts, and market access developments for meaningful investment updates.

Sep 1, 2026

Phathom Pharmaceuticals Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Activist Filings

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research